Professional
Added to YB: 2024-01-24
Pitch date: 2024-01-24
EVO [bullish]
Evotec SE
-64.82%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
Market Cap
EUR 1.5B
Pitch Price
EUR 14.86
Price Target
18.60 (+256%)
Dividend
N/A
EV/EBITDA
65.10
P/E
-9.02
EV/Sales
2.21
Sector
Life Sciences Tools and Services
Category
value
Show full summary:
RBC upgrades $EVO to Outperform
$EVO at 5y low on CEO exit & share dealing probe; 8x 2025 EBITDA for double-digit grower looks cheap. Cyber attack & biotech funding headwinds, but BMS/Sandoz/DoD deals support biz. €18.6 PT has 20% risk discount; €23+ on strong 2025 EBITDA growth.
Read full article (2 min)